

process – all of which have been key components of our additional investor support. We are very excited about our upcoming pre-clinical trials this year.”

FAST has had other recent fundraising successes, including an announced commitment by the Purdue Research Foundation/Purdue University Emerging Innovations Fund to invest \$200,000 and a \$1.1 million grant from the National Institutes of Health. The company has also received significant follow on funding from its original shareholders and angel investors.

The company is planning to run a pilot human study in 2010.

About BioCrossroads

BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow the life sciences, a public-private collaboration that supports the region’s research and corporate strengths while encouraging new business development.

BioCrossroads provides money and support to life sciences businesses, launches new life sciences businesses, expands collaboration and partnerships among Indiana's life science institutions, expands science education and markets Indiana's life sciences industry.

About the Indiana Seed Fund I

The \$6 million, return-driven Indiana Seed Fund was launched in June 2005 and is managed by BioCrossroads with funding coming from BioCrossroads, the Indiana Finance Authority and the Indiana Economic Development Corporation. The Seed Fund provides working capital in the range of \$50,000-\$500,000 to promising Indiana life sciences companies at the preliminary stages of operation.

About FAST

FAST’s patent-pending device and in vivo methodology provide rapid and accurate measurement of true kidney function for use in hospitals, intensive care units, cardiac catheterization labs, and physician offices. This technology enables healthcare providers to improve outcomes for the rapidly growing patient population suffering with acute kidney injury.

###